|
Phenobarbitone
drug data and news
Phenobarbitone drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
| Generic name |
Phenobarbitone
|
| Brand Names/Synonyms |
Adonal; Aephenal; Agrypnal; Amylofene; Aphenylbarbit; Aphenyletten; Barbenyl; Barbinal; Barbiphen; Barbiphenyl; Barbipil; Barbita; Barbivis; Barbonal; Barbophen; Bardorm; Bartol; Bialminal; Blu-Phen; Cabronal; Calmetten; Calminal; Cardenal; Chinoin; Codibarbita; Coronaletta; Cratecil; Damoral; Dezibarbitur; Dormina; Dormiral; Dormital; Doscalun; Duneryl; Ensobarb; Ensodorm; Epanal; Epidorm; Epilol; Episedal; Epsylone; Eskabarb; Etilfen; Euneryl; Fenbital; Fenemal; Fenobarbital; Fenosed; Fenylettae; Gardenal; Gardepanyl; Glysoletten; Haplopan; Haplos; Helional; Hennoletten; Henotal; Hypnaletten; Hypnette; Hypno-Tablinetten; Hypnogen; Hypnolone; Hypnoltol; Hysteps; Lefebar; Leonal; Lephebar; Lepinal; Lepinaletten; Linasen; Liquital; Lixophen; Lubergal; Lubrokal; Lumen; Lumesettes; Lumesyn; Luminal; Lumofridetten; Luphenil; Luramin; Molinal; Neurobarb; Nirvonal; Noptil; Nova-Pheno; Nunol; Parkotal; Pharmetten; Phen-Bar; Phenaemal; Phenemal; Phenemalum; Phenobal; Phenobarbital; Phenobarbitol; Phenobarbitone; Phenobarbituric Acid; Phenobarbyl; Phenoluric; Phenolurio; Phenomet; Phenonyl; Phenoturic; Phenylethylbarbiturate; Phenylethylbarbituric Acid; Phenylethylmalonylurea; Phenyletten; Phenyral; Phob; Polcominal; Promptonal; Seda-Tablinen; Sedabar; Sedicat; Sedizorin; Sedlyn; Sedofen; Sedonal; Sedonettes; Sevenal; Sinoratox; Sk-Phenobarbital; Solfoton; Solfoton Talpheno; Solu-Barb; Sombutol; Somnolens; Somnoletten; Somnosan; Somonal; Spasepilin; Starifen; Starilettae; Stental; Stental Extentabs; Talpheno; Teolaxin; Teoloxin; Thenobarbital; Theoloxin; Triabarb; Tridezibarbitur; Triphenatol; Versomnal; Zadoletten; Zadonal |
| Indication |
For the treatment of Epilepsy |
|
Sponsored links
|
|
Description |
Not Available |
| Pharmacology |
Phenobarbital, the longest-acting barbiturate, is used for its anticonvulsant and sedative-hypnotic properties in the management of all seizure disorders except absence (petit mal). |
| Mechanism Of Action |
Phenobarbital acts on GABAA receptors, increasing synaptic inhibition. This has the effect of elevating seizure threshold and reducing the spread of seizure activity from a seizure focus. Phenobarbital may also inhibit calcium channels, resulting in a decrease in excitatory transmitter release. The sedative-hypnotic effects of phenobarbital are likely the result of its effect on the polysynaptic midbrain reticular formation, which controls CNS arousal. |
Phenobarbitone News
(When available) |
[an error occurred while processing this directive] |
| Dosage Forms |
Tablets and Elixir |
| Drug_Category |
Hypnotics and Sedatives; Anticonvulsants; |
| Absorption |
absorbed in varying degrees following oral, rectal or parenteral administration. The salts are more rapidly absorbed than are the acids. The rate of absorption is increased if the sodium salt is ingested as a dilute solution or taken on an empty stomach |
| Interactions |
[an error occurred while processing this directive]Toxicity |
CNS and respiratory depression which may progress to Cheyne- Stokes respiration, areflexia, constriction of the pupils to a slight degree (though in severe poisoning they may wshow paralytic dilation), oliguria, tachycardia, hypotension, lowered body temperature, and coma. Typical shock syndrome (apnea, circulatory collapse, respiratory arrest, and death) may occur. LD50=mg/kg(orally in rat) |
| Organisms Affected |
Humans and other mammals |
| Chemical IUPAC Name |
5-ethyl-5-phenyl-hexahydropyrimidine-2,4,6-trione |
| Chemical Formula |
C12H12N2O3 |
| Molecular Weight |
232.235 g/mol |
| Smiles String |
CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2 |
| Melting Point |
174 °C |
| Water Solubility |
<0.01 g/100 mL |
| State |
Solid |
| LogP/Hphobicity |
1.777 |
| Isoelectric Point |
Not Available |
| Biotransformation |
Hepatic |
| Half Life |
53 to 118 hours (mean: 79 hours) |
| Protein Binding [%] |
50% |
| RxList Link |
Not Available>RXlist |
|
Sponsored links
|
|
| Drug Reference |
Not Available |
| Drug Type |
Approved Drug |
| Accession No |
APRD00184 |
| CAS Registry Number |
50-06-6 |
| KEGG Compound ID |
Not Available |
| PubChem ID |
SID:419552 |
| PharmGKB ID |
Not Available |
| SwissProt ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
Not Available
|
|
|
